Neurological Surgery 脳神経外科52巻4号

2024年07月発行

特集 髄膜腫の現在—最新の知識を活かした最善の治療のために Ⅲ 髄膜腫の遺伝子・分子異常解析と予後予測

髄膜腫の遺伝子・分子異常解析と予後予測のいま

著者： 岡野淳¹

所属機関： ¹東京警察病院脳神経外科

ページ範囲：P.718 - P.724

Point
・髄膜腫の発生に関わる遺伝子変異，メチル化ステータスなどの研究が進んできた．
・分子生物学的知見を利用した統合分類は従来のWHO gradingよりも予後の予測が正確である．
・今後，分子標的治療薬への応用や，放射線感受性マーカーの開発などが期待される．

参考文献

1）Seizinger BR, et al：Molecular genetic approach to human meningioma：loss of genes on chromosome 22. Proc Natl Acad Sci U S A 84：5419-5423, 1987

2）Riemenschneider MJ, et al：Histological classification and molecular genetics of meningiomas. Lancet Neurol 5：1045-1054, 2006

3）Clark VE, et al：Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339：1077-1080, 2013

4）Brastianos PK, et al：Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45：285-289, 2013

5）Clark VE, et al：Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48：1253-1259, 2016

6）Reuss DE, et al：Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125：351-358, 2013

7）Yuzawa S, et al：Genetic landscape of meningioma. Brain Tumor Pathol 33：237-247, 2016

8）Strickland MR, et al：Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg 127：438-444, 2017

9）Boetto J, et al：SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol 19：345-351, 2017

10）Okano A, et al：Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep 11：6987, 2021　doi:10.1038/s41598-021-86298-9

11）Jungwirth G, et al：Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathol Commun 7：140, 2019　doi:10.1186/s40478-019-0793-4

12）Sahm F, et al：TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 108：djv377, 2016　doi:10.1093/jnci/djv377

13）Sievers P, et al：CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140：409-413, 2020

14）Sahm F, et al：DNA methylation-based classification and grading system for meningioma：a multicentre, retrospective analysis. Lancet Oncol 18：682-694, 2017

15）Maas SLN, et al：German Consortium on Aggressive Meningiomas（KAM）. Integrated molecular-morphologic meningioma classification：a multicenter retrospective analysis, retrospectively and prospectively validated. J Clin Oncol 39：3839-3852, 2021

16）Nassiri F, et al：A clinically applicable integrative molecular classification of meningiomas. Nature 597：119-125, 2021

17）Choudhury A, et al：Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54：649-659, 2022

18）Bayley JC 5th, et al：Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci Adv 8：eabm6247, 2022　doi:10.1126/sciadv.abm6247

19）Wang JZ, et al：The multiomic landscape of meningiomas：a review and update. J Neurooncol 161：405-414, 2023

20）Driver J, et al：A molecularly integrated grade for meningioma. Neuro Oncol 24：796-808, 2022

21）Horbinski C, et al：The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. Neurooncol Adv 3：vdab085, 2021　doi:10.1093/noajnl/vdab085

22）Okano A, et al：Advances in molecular biological and translational studies in World Health Organization grades 2 and 3 meningiomas：a literature review. Neurol Med Chir（Tokyo）62：347-360, 2022

23）Goldbrunner R, et al：EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23：1821-1834, 2021